Equities analysts forecast that La Jolla Pharmaceutical (NASDAQ:LJPC) will announce earnings per share of ($1.12) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for La Jolla Pharmaceutical’s earnings. The highest EPS estimate is ($1.09) and the lowest is ($1.17). La Jolla Pharmaceutical posted earnings of ($2.02) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 44.6%. The business is expected to announce its next quarterly earnings report on Wednesday, August 14th.

On average, analysts expect that La Jolla Pharmaceutical will report full year earnings of ($4.43) per share for the current fiscal year, with EPS estimates ranging from ($4.70) to ($4.18). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.55) per share, with EPS estimates ranging from ($3.25) to ($1.45). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for La Jolla Pharmaceutical.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.31) by $0.14. La Jolla Pharmaceutical had a negative return on equity of 337.55% and a negative net margin of 1,324.04%. The firm had revenue of $4.40 million for the quarter, compared to analyst estimates of $4.98 million.

Several equities analysts recently issued reports on the company. Zacks Investment Research lowered La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. ValuEngine upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, April 4th. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of La Jolla Pharmaceutical in a research report on Wednesday, April 24th. Cowen restated a “buy” rating on shares of La Jolla Pharmaceutical in a research report on Tuesday, March 5th. Finally, JPMorgan Chase & Co. upgraded La Jolla Pharmaceutical from an “underweight” rating to a “neutral” rating and reduced their price target for the stock from $18.00 to $9.00 in a research report on Wednesday, January 23rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. La Jolla Pharmaceutical has an average rating of “Hold” and an average target price of $30.63.

LJPC traded up $0.03 on Tuesday, hitting $5.82. 291,131 shares of the company were exchanged, compared to its average volume of 831,522. La Jolla Pharmaceutical has a 12 month low of $5.01 and a 12 month high of $38.39. The firm has a market cap of $157.72 million, a price-to-earnings ratio of -0.74 and a beta of 1.41.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tang Capital Management LLC grew its position in La Jolla Pharmaceutical by 27.3% during the 1st quarter. Tang Capital Management LLC now owns 4,938,893 shares of the biopharmaceutical company’s stock worth $31,757,000 after acquiring an additional 1,060,000 shares during the last quarter. FMR LLC lifted its stake in shares of La Jolla Pharmaceutical by 3.3% in the 1st quarter. FMR LLC now owns 4,061,425 shares of the biopharmaceutical company’s stock valued at $26,115,000 after purchasing an additional 128,074 shares during the period. Broadfin Capital LLC lifted its stake in shares of La Jolla Pharmaceutical by 2.4% in the 1st quarter. Broadfin Capital LLC now owns 1,994,911 shares of the biopharmaceutical company’s stock valued at $12,827,000 after purchasing an additional 47,370 shares during the period. Sectoral Asset Management Inc lifted its stake in shares of La Jolla Pharmaceutical by 6.7% in the 4th quarter. Sectoral Asset Management Inc now owns 1,759,171 shares of the biopharmaceutical company’s stock valued at $16,589,000 after purchasing an additional 110,399 shares during the period. Finally, BlackRock Inc. lifted its stake in shares of La Jolla Pharmaceutical by 1.3% in the 4th quarter. BlackRock Inc. now owns 1,498,561 shares of the biopharmaceutical company’s stock valued at $14,132,000 after purchasing an additional 18,557 shares during the period.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Featured Article: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.